AIMS: The aim of the study was to investigate the pharmacokinetics of recombinant human interleukin-2 (rhIL-2) in patients with metastatic renal cell carcinoma following different subcutaneous (s.c.) administration regimens. METHODS: RhIL-2 was administered subcutaneously to 10 patients according to two different dosing regimens: group A received 20 x 10(6) IU m(-2) once daily and group B 10 x 10(6) IU m(-2) twice daily (every 12 h). Additionally, in all patients the influence of soluble interleukin-2 receptor (sIL-2R) on the pharmacokinetics of rhIL-2 was investigated. RESULTS: The mean area under the serum concentration-time curve to 24 h (AUC(0,24 h)) was 627 IU ml(-1) h in treatment group A and 1130 IU ml(-1) h (P=0.029) in treatment group B. In both study groups Cmax and AUC(0,12 h) were not significantly different. Seventy-two hours after the beginning of s.c. rhIL-2 therapy the sIL-2R increased significantly (P=0.016), and sIL-2R levels over 1200 pmol l(-1) seemed to reduce the AUC. CONCLUSIONS: In patients with metastatic renal cell cancer administration of 20 x 10(6) IU m(-2) of rhIL-2 s.c. in two daily doses (10 x 10(6) IU m(-2) every 12 h) provides better bioavailability and is preferable to the single dose administration.
RCT Entities:
AIMS: The aim of the study was to investigate the pharmacokinetics of recombinant humaninterleukin-2 (rhIL-2) in patients with metastatic renal cell carcinoma following different subcutaneous (s.c.) administration regimens. METHODS: RhIL-2 was administered subcutaneously to 10 patients according to two different dosing regimens: group A received 20 x 10(6) IU m(-2) once daily and group B 10 x 10(6) IU m(-2) twice daily (every 12 h). Additionally, in all patients the influence of soluble interleukin-2 receptor (sIL-2R) on the pharmacokinetics of rhIL-2 was investigated. RESULTS: The mean area under the serum concentration-time curve to 24 h (AUC(0,24 h)) was 627 IU ml(-1) h in treatment group A and 1130 IU ml(-1) h (P=0.029) in treatment group B. In both study groups Cmax and AUC(0,12 h) were not significantly different. Seventy-two hours after the beginning of s.c. rhIL-2 therapy the sIL-2R increased significantly (P=0.016), and sIL-2R levels over 1200 pmol l(-1) seemed to reduce the AUC. CONCLUSIONS: In patients with metastatic renal cell cancer administration of 20 x 10(6) IU m(-2) of rhIL-2 s.c. in two daily doses (10 x 10(6) IU m(-2) every 12 h) provides better bioavailability and is preferable to the single dose administration.
Authors: A R Mueller; K P Platz; I Wiehe; F Monticelli; J Lierath; M Keitel; R Streich; W O Bechstein; P Neuhaus Journal: Transpl Int Date: 1996 Impact factor: 3.782
Authors: Yash Agarwal; Lauren E Milling; Jason Y H Chang; Luciano Santollani; Allison Sheen; Emi A Lutz; Anthony Tabet; Jordan Stinson; Kaiyuan Ni; Kristen A Rodrigues; Tyson J Moyer; Mariane B Melo; Darrell J Irvine; K Dane Wittrup Journal: Nat Biomed Eng Date: 2022-01-10 Impact factor: 29.234
Authors: Gautam Goel; Jason A Tye-Din; Shuo-Wang Qiao; Amy K Russell; Toufic Mayassi; Cezary Ciszewski; Vikas K Sarna; Suyue Wang; Kaela E Goldstein; John L Dzuris; Leslie J Williams; Ramnik J Xavier; Knut E A Lundin; Bana Jabri; Ludvig M Sollid; Robert P Anderson Journal: Sci Adv Date: 2019-08-07 Impact factor: 14.136